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The chromatin environment is essential for the correct specification and preservation of cell identity through
modulation and maintenance of transcription patterns. Many chromatin regulators are required for develop-
ment, stem cell maintenance, and differentiation. Here, we review the roles of the polycomb repressive com-
plexes, PRC1 and PRC2, and the HDAC1- and HDAC2-containing complexes, NuRD, Sin3, and CoREST, in
stem cells, development, and cancer, as well as the ongoing efforts to develop therapies targeting these
complexes in human cancer. Furthermore, we discuss the role of repressive complexes inmodulating thresh-
olds for gene activation and their importance for specification and maintenance of cell fate.Introduction
The organization of DNA into chromatin is essential for the pres-
ervation of genomic integrity in eukaryotic cells and is required
for the correct transmission of genetic information over genera-
tions. In addition to the physical role of compacting and protect-
ing DNA, the chromatin conformation is closely correlated with
the expression state of the genes within its structure. Genes pre-
sent in a dense chromatin environment are less available to the
transcriptional machinery and transcribed to a lesser extent
than genes found in looser, and more permissive, chromatin
domains. Chromatin is subject to highly dynamic modifications,
playing important roles in regulating the availability of DNA and
thus gene expression. This regulation includes the exchange of
histone variants, nucleosome remodeling by ATP-dependent re-
modeling complexes, as well as posttranslational modifications
of DNA and histones (Kouzarides, 2007).
Protruding N-terminal tails of the core histones (Luger et al.,
1997), as well as the linker histone H1, are subject to a vast array
of posttranslational modifications, some of which are associated
with the transcriptional state of the underlying gene, whereas
others appear to play roles in chromatin processes such as
cell-cycle regulation or the DNA damage response. Histone
modifications have different biochemical functions: One, they
serve as docking sites for proteins containing conserved do-
mains interacting with the modified residues, thus recruiting
other factors to relevant genomic loci. Two, charged modifica-
tions, such as lysine acetylation, neutralize the positive charge
of the histones, leading to decreased binding of the negatively
charged DNA strand, thus loosening the chromatin structure
and promoting transcriptional activity (Kouzarides, 2007).
The various cells of an adult organism display distinct pheno-
types, yet they all rely on the same underlying genome. In order
to establish cell identity, the correct set of genes must be tran-
scribed, while other genes must be kept in a silent state, and
this pattern of gene expression must be maintained in the differ-
entiated cell and propagated through cell generations. Because
chromatin regulators ensure stable and heritable cell and tissuespecific gene-expression patterns over subsequent cell genera-
tions, they are important for specifying andmaintaining cell iden-
tity (Orkin and Hochedlinger, 2011).
With chromatin modifiers being important for maintaining cell
identity, it is not surprising that their deregulation can have dele-
terious effects on cell fate and functions. Indeed, many chro-
matin modifiers are essential for normal development and are
often found deregulated in human disease, including cancer.
One intriguing prospect of this is that whereas genetic mutations
are irreversible and thus difficult to target clinically, chromatin
modifications are reversible and might thus present promising
therapeutic targets. In fact, intense research efforts are currently
going into developing inhibitors specifically targeting chromatin-
associated proteins, some of which are already in clinical trials
and others in clinical use (Helin and Dhanak, 2013).
In this review, we discuss the role of chromatin-mediated
transcriptional repression with a particular focus on polycomb
repressive complexes, PRC1 and PRC2, and the HDAC1- and
HDAC2-containing complexes, SIN3, NuRD, and CoREST. We
describe their mechanisms of action in stem cells and develop-
ment, as well as their deregulation in cancer and emerging stra-
tegies for targeting them therapeutically.
Polycomb Repressive Complexes
The Polycomb group (PcG) proteins were originally identified in
Drosophila, as transcriptional repressors required for the correct
spatiotemporal expression of developmental regulators along
the body axis andmutant flies develop abnormally with homeotic
transformations. The PcG proteins assemble into large multi-
protein complexes, the best-characterized being PRC1 and
PRC2 (Figure 1). PRC1 homologs have been identified in meta-
zoan species from flies to mammals, whereas the PRC2 homo-
logs are also found in plants and nematodes (Margueron and
Reinberg, 2011).
PRC1. Drosophila PRC1 consists of Pc (Polycomb, a chromo-
domain-containing protein with affinity for H3K27me3), dRing
(catalyzing H2A ubiquitylation), Psc (Posterior sex combs, in-
volved in chromatin compaction), and Ph (Polyhomeotic).Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc. 735
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Figure 1. Schematic Representation of
Polycomb Repressive Complexes
PRC2 catalyzes methylation of H3K27 (red cir-
cles). Several publications have shown that
PRC2 recruitment relies on interacting proteins
(such as JARID2, AEBP2, and PCL1-3), transient
interactions with cell-type-specific transcription
factors or noncoding RNAs. Canonical (CBX-
containing) PRC1 complexes are recruited
(dashed arrow) to H3K27me3, while noncanonical
(PRC2-independent) PRC1 is recruited (dashed
arrow) to CpG islands (blue circles) by KDM2B.
Both CBX-containing and PRC2-independent
PRC1 complexes catalyze the ubiquitylation of
H2AK119 (red hexagons).
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Drosophila PRC1 components with five CBX homologs (CBX2/
4/6/7/8), two ubiquitin ligases (RING1A/B), six PCGF family
members (PCGF1–6, homologous to Psc), and three PHC family
members (Ph homologs). In mammalian cells, PRC1 catalyzes
H2AK119 ubiquitylation (H2AK119ub1) and promotes chromatin
compaction (Di Croce and Helin, 2013).
PRC2. Mammalian PRC2 contains the core components EZH2
or its closely related homolog EZH1 (homologs of Drosophila E
[z]), EED (homolog of Esc), and SUZ12 (homolog of Su[z]12), all
three of which are required for catalytic activity in vitro, whereas
association with the histone chaperone RBBP4/7 seems to be
required for catalytic activity in vivo. The EZH component con-
tains a SET domain, which catalyzes the methylation of lysine
27 of histone H3 (Margueron and Reinberg, 2011).
Transcriptional Repression by PRCs. Whereas H3K27 is the
essential physiological substrate for PRC2 (Pengelly et al.,
2013), the precise functional importance of PRC-mediated his-
tone marks remains unclear. The functional role of H3K27me3
has primarily been studied as a recruitment mechanism for
CBX-containing PRC1 complexes, and, in Drosophila, the cata-
lytic activity of E(z) is required for target gene repression (Mu¨ller
et al., 2002), whereas H2AK119ub1 is believed to promote chro-
matin compaction and transcriptional repression. In vitro data
show that PRCs promote condensation of nucleosomal arrays
(Francis et al., 2004), and PRC binding in Drosophila mediates
chromatin compaction and organization into functional domains,
called PcG bodies, as well as long-range interactions important
for higher-order chromatin organization (Bantignies et al., 2011;
Sexton et al., 2012). Recently, the E3 ligase activity of the Ring1
component of PRC1 was shown to be dispensable for recruit-
ment to and compaction of chromatin at the Hox loci in mESCs
(Endoh et al., 2012). However, the catalytic activity was indis-
pensable for target gene repression, indicating that H2A ubiqui-
tylation and chromatin condensation represent two separate
mechanisms of PRC1-mediated repression (Endoh et al.,
2012). Alternative roles of H2AK119ub1 in PRC-mediated
repression include prevention of H3K4me3 deposition, inhibition
of RNA polymerase II activity, and prevention of H2A-H2B dimer
eviction from transcribed regions (Di Croce and Helin, 2013).736 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.Recruitment of Polycomb Repressive
Complexes. In Drosophila, PcG pro-
teins are recruited to DNA stretches
termed Polycomb Response Elements(PREs). A distinct PRE for mammalian cells remains elusive,
but mammalian PRCs bind CpG rich promoters of their target
genes (Ku et al., 2008), and CpG-rich sequences have been
shown to mediate PRC2 recruitment (Mendenhall et al., 2010).
Several different recruitment mechanisms for PRC2 have been
suggested, including association with near-stoichiometric inter-
action partners (such as PCL1-3, AEBP2, JARID2), association
with transcription factors, and recruitment by ncRNA (Di Croce
and Helin, 2013). The WD40 domains of the RBBP4/7 subunit
confer general histone-binding activity to PRC2, while those of
EED specifically interact with H3K27me3, thus providing a
potential mechanism for spreading and propagation of the
mark. In addition, JARID2 and AEBP2 have both been shown
to confer weak CpG-rich DNA-binding activity to the complex,
while the Tudor domains of PCL1-3 were recently shown to
bind H3K36me2/3 (Di Croce and Helin, 2013). The involvement
of ncRNAs in PRC recruitment has been most extensively
studied in the context of X chromosome inactivation. The accu-
mulation of H3K27me3 on the inactive X chromosome is depen-
dent on XIST expression, and the A repeats of XIST have been
shown to bind PRC2 (Zhao et al., 2008). However, XIST lacking
the A repeats is capable of recruiting PRC2, indicating the
involvement of other domains of XIST in PRC2 recruitment (Kohl-
maier et al., 2004).While a number of studies show association of
ncRNAs with PRC2 members, the reports differ in the types of
RNAs identified, specific binding areas of the RNAs, and the
PRC2 component involved in the interaction, and the exact
role of ncRNAs in PRC2 recruitment remains unclear (da Rocha
et al., 2014; Davidovich et al., 2013; Kaneko et al., 2014; Zhao
et al., 2010).
Several lines of evidence obtained in Drosophila and mamma-
lian cells have shown that PRC1 recruitment to target sites is
dependent on PRC2 and H3K27me3. However, recent studies
in PRC2 knockout mESCs have shown only a minor decrease
in H2AK119ub1 levels despite a global loss of H3K27me3
(Leeb et al., 2010). An explanation for this observation has
been provided by the characterization of PRC2-independent
RING1-containing complexes without any CBX component,
which rely on their complex partners RYBP/YAF2 and
L3MBTL2, as well as the association with DNA binding proteins
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Figure 2. Schematic Representation of
HDAC1- and HDAC2-Containing
Complexes
HDAC1 and HDAC2 of SIN3, NuRD, and CoREST
catalyze the removal of acetyl groups from histone
tails (green triangles). The NuRD subunits CHD3/4
are ATP-dependent chromatin remodelers and
LSD1present inCoREST (and possibly alsoNuRD)
catalyzes demethylation of H3K4me1/2 (green
circles). Recruitment of HDAC1- and HDAC2-
containing complexes is thought to rely on chro-
matin-binding domains within each complex or
additional interaction partners (not depicted).
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(Farcas et al., 2012; Gao et al., 2012; Qin et al., 2012; Tavares
et al., 2012; Wu et al., 2013). Similar to what has been shown
in Drosophila (Lagarou et al., 2008), the mammalian KDM2B-
RING1B complex appears to have higher catalytic activity
toward H2AK119ub1 than PRC1.
Accompanying the changes in transcriptional programs during
differentiation, PRCbinding changes dynamically (Bracken et al.,
2006; Mohn et al., 2008). Whether the patterns of PRC binding in
various cell types depend on differential expression of interac-
tion partners or ncRNAs or whether PRC binding differs simply
as a consequence of differential gene-expression patterns and
recruitment to untranscribed genes is still unclear. Elucidating
the mechanisms regulating PRC binding to target genes is
essential for our understanding of the nature of PRC-mediated
transcriptional repression.
HDAC1- and HDAC2-Containing Complexes
HDAC1 and HDAC2 are highly homologous class I histone
deacetylases found in large multimeric complexes, the most
extensively studied being Sin3, NuRD, and CoREST (Figure 2),
which are found in species from yeast to human. In addition
to the HDAC1 and HDAC2 catalytic core and RBBP4/7 that are
shared among the complexes, they incorporate different sub-
units, thus providing target specificity or additional catalytic
activities. Importantly, many of the subunits have several homo-
logs, allowing for combinatorial assembly of specific complexes
with context-dependent functions (Kelly and Cowley, 2013).
SIN3. Mammalian genomes encode two homologs of SIN3
(SIN3A/B), which associate individually with HDAC1 and HDAC2,
RBBP4 and RBBP7, SDS3, and the SIN3-associated proteins
SAP18 and SAP30 to form the core SIN3 complex. Different
studies have identified additional interaction partners including
MeCP2 (methyl-CpG-bindingprotein), RBP1 (RB-bindingprotein),
BRMS1 (breast cancer metastasis suppressor), ING1/2 (inhibitor
of growth), SAP25, SAP130, and SAP180, as well as the histone
demethylaseRBP2/KDM5A (HayakawaandNakayama,2011;Ka-
damb et al., 2013).
NuRD. The NuRD (nucleosome remodeling deacetylase) com-
plex couples two important chromatin-modifying activities,
namely nucleosome remodeling through the ATP-dependentCell Stem CelCHD3/4 helicase subunit and histone
deacetylation catalyzed by HDAC1 and
HDAC2. Additional components include
the scaffolding proteins GATAD2A/B,
conferring histone-binding properties to
the complex, while the MBD2/3 andMTA1/2/3 subunits mediate binding to DNA and transcription
factors, respectively (Hayakawa and Nakayama, 2011; Lai and
Wade, 2011). Some results have suggested that NuRD interacts
with the histone demethylase LSD1/KDM1A, potentially adding
yet another catalytic activity to its repertoire (Wang et al.,
2009b). However, this association is not observed in other puri-
fications, possibly reflecting context-specific interactions.
CoREST. Originally described as corepressor of REST (RE1-
silencing transcription factor), CoREST was subsequently found
in complex with HDAC1 and HDAC2 and RBBP4/7 (although not
retrieved in some purifications) with additional subunits including
Sox-like protein, ZNF217, BHC80, and the histone demethylase
LSD1 (Hayakawa and Nakayama, 2011). LSD1 has catalytic ac-
tivity toward H3K9me1/2 and H3K4me1/2 (Metzger et al., 2005;
Shi et al., 2004). However, in the context of CoREST, LSD1
seems to preferentially target H3K4me1/2, while primarily exert-
ing its function as a H3K9 demethylase when associated with nu-
clear receptors (Kooistra and Helin, 2012).
Transcriptional Regulation by HDAC1- and HDAC2-Containing
Complexes. SIN3, NuRD, and CoREST are all large, multimeric
complexes that serve as scaffolds for assembling different cata-
lytic activities at relevant genomic loci. For NuRD, the CHD3/4
helicase activity has been shown to promote deacetylase activ-
ity, possibly by promoting the accessibility of the nucleosome
substrate through ATP-dependent nucleosome sliding (Xue
et al., 1998). It is noteworthy that all three complexes combine
their core deacetylase activity with demethylase interaction part-
ners. For CoREST, the two catalytic activities appear to be inter-
dependent with deacetylation promoting demethylation (Lee
et al., 2006a), pointing to a functional interplay extending beyond
mere colocalization.
In accordance with histone acetylation being associated with
transcriptional activation, HDAC-containing complexes revers-
ing this modification are traditionally described as corepressors
promoting transcriptional repression of their target genes. Impor-
tantly, however, it has been shown that dynamic acetylation and
deacetylation is required for active transcription to occur, thus
pointing to important roles of HDAC-containing complexes in
activating transcription in addition to their function as corepres-
sors (Clayton et al., 2006; Kelly and Cowley, 2013). Indeed,l 14, June 5, 2014 ª2014 Elsevier Inc. 737
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that HDACs also colocalize with acetyltransferases at transcrip-
tionally active loci, presumably acting to reset acetylation levels
after gene activation (Wang et al., 2009c). Thus, the transcrip-
tional regulation exerted by HDAC1- and HDAC2-containing
complexes might be highly context dependent.
Recruitment of HDAC1- and HDAC2-Containing Complexes.
Recruitment of the HDAC1- and HDAC2-containing complexes
seems to rely on cell-type-specific transcription factor binding
and chromatin-binding domains within certain subunits (Haya-
kawa and Nakayama, 2011). Each of the complexes contain at
least two subunits with histone-binding properties such as
PHD-fingers, chromodomains and Tudor domains, as well as
the WD40 repeats of RBBP4/7 (Kelly and Cowley, 2013).
The existence of several homologs for most of the compo-
nents indicates that specific complex composition might confer
distinct binding patterns and influence their biological function in
different cell types (Kelly and Cowley, 2013). For instance, NuRD
complex containing MBD2 is functionally distinct from MBD3-
NuRD (LeGuezennec et al., 2006). MBD2 recruits NuRD tometh-
ylated CpGs, whereas MBD3 is unable to bind methyl-cytosine
due to amino acid substitutions in the methyl-binding domain.
However, NuRD is recruited to some target genes independently
of their methylation status, and the MBD component is thus only
partly responsible for NuRD recruitment (Baubec et al., 2013).
Similarly, the MTA proteins are incorporated into distinct NuRD
complexes with differential transcription factor binding and
recruitment to specific genomic loci (Lai and Wade, 2011).
Thus, for PRCs and HDAC1- and HDAC2-containing com-
plexes, it seems that specific subunit composition and associa-
tion with cell-type-specific interaction partners is important for
regulating their recruitment and biological function.
Chromatin Repressive Complexes in Pluripotent Stem
Cells
ESCs display an open and permissive chromatin structure with
low levels of DNA methylation and a greater abundance of acti-
vating histone modifications, such as H3K4me3 and histone
acetylation. In addition, structural proteins such as heterochro-
matin protein 1 (HP1), the linker histone H1, and the core his-
tones display highly dynamic kinetics in their association with
chromatin in ESCs, further opening the chromatin structure
(Azuara et al., 2006; Meshorer et al., 2006). The hyperdynamic
nature of ESC chromatin correlates with a very high level of tran-
scriptional activity and a high abundance of general transcription
factors and chromatin modifiers (Efroni et al., 2008), central to
maintaining transcriptional patterns in the open chromatin struc-
ture. Upon differentiation, the overall chromatin structure shifts
toward a tighter, more restrictive configuration with decreased
transcriptional activity and concomitant accumulation of
H3K27me3 (Zhu et al., 2013), as well as induction of large
H3K9me3-positive heterochromatic foci (Meshorer et al., 2006).
Chromatin regulators along with tightly regulated transcription
factor circuits play important roles in balancing self-renewal and
pluripotency in ESCs, and the open chromatin environment
appears to be important for the maintenance of pluripotency.
Conversely, the open, permissive chromatin environment neces-
sitates the action of chromatin repressive complexes in order to
protect against inappropriate transcription of differentiation fac-
tors, as well as for the orchestration of differentiation through the738 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.timely repression of pluripotency-associated genes (Orkin and
Hochedlinger, 2011).
Polycomb Repressive Complexes in Embryonic Stem Cells.
PRCs are highly expressed in ESCs and have been shown to
bind CpG-rich promoters of genes for transcription factors and
signaling molecules controlling development (Boyer et al.,
2006; Bracken et al., 2006; Lee et al., 2006b). In addition, PcG
proteins and their marks are found at some repetitive elements
and involved in imprinting and X chromosome inactivation
(Casa and Gabellini, 2012).
While the PRC2 components are essential for mouse develop-
ment, mESCs lacking Eed, Suz12, or Ezh2 can be derived from
knockout embryos, yielding similar phenotypes with retention
of self-renewal capacity, loss of H3K27me2/3 and in vitro differ-
entiation defects. Consistent with the in vitro defects, chimeric
embryo complementation studies show that knockout mESCs
initiate differentiation but display abnormal long-term repression
of pluripotency factors and lack robust induction of differentia-
tion factors (Chamberlain et al., 2008; Montgomery et al., 2005;
Pasini et al., 2007; Shen et al., 2008). Notably, the passage num-
ber of Eed/ cells influences the phenotype: high-passage
Eed/ cells display more pronounced derepression of target
genes and a global loss H3K27me1, whereas the phenotype of
low-passage Eed/ cells appears identical to those of Ezh2/
and Suz12/ cells (Chamberlain et al., 2008).
Ring1b-deficientmESCs have reduced levels of H2AK119ub1,
a slight deregulation of some target genes and a loss of differen-
tiation potential (Leeb and Wutz, 2007), whereas Ring1a/Ring1b
double knockout mESCs lose the ability to self-renew after a few
passages and show defects in cell-cycle regulation, pointing to
PRC2-independent roles of Ring1a/Ring1b (Endoh et al., 2008).
Knockdown studies show that the noncanonical PRC1 compo-
nents Rybp or Kdm2/Fbxl10 are dispensable for self-renewal,
while loss of either factor diminishes H2AK119ub1 levels and
compromises the in vitro differentiation potential (Gao et al.,
2012; Wu et al., 2013). Recently, different Cbx subunits of
PRC1 were shown to have specific roles with Cbx7 being
required for maintaining the pluripotent state of mESCs, with a
shift in composition to Cbx2/4 being important during differenti-
ation (Morey et al., 2012).
HDAC1- and HDAC2-Containing Complexes in Embryonic Stem
Cells. Hdac1 and Hdac2 are both dispensable for mESC self-
renewal, but whereas Hdac2/ cells retain their in vitro differen-
tiation potential, Hdac1 knockout disrupts normal differentiation
(Dovey et al., 2010). Several NuRD subunits have been shown to
interact with core pluripotency factors, including Oct4 and
Nanog, forming the NODE complex (Nanog- and Oct4-associ-
ated deacetylase) (Liang et al., 2008), whichmight be functionally
distinct from Mbd3-containing NuRD. While the relative contri-
butions of different Hdac1- and Hdac2-containing complexes
remain unclear, several studies show important roles of subunits
of each of these complexes in mESCs.
In vitro culture of Sin3a/ blastocysts yield smaller colonies
and insufficient outgrowth of the ICM, showing important roles
of Sin3a in the establishment of mESCs (Cowley et al., 2005),
consistent with the peri-implantation lethality observed for
Sin3a/mice.Mbd3-deficient mESCs can be derived and prop-
agated in culture but display defects during differentiation (Kaji
et al., 2006; Rais et al., 2013). Knocking out Lsd1 in mESCs leads
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(A) The chromatin environment sets thresholds for
gene activation, ensuring that persistent exposure
to appropriate signals (e.g., increasing transcrip-
tion factor levels) is required for transcriptional
activation. Loss of chromatin repressive com-
plexes (dashed line) lowers the threshold and in-
creases transcriptional noise.
(B) Changes in chromatin thresholds in turn alter
the barriers against changes in cell identity medi-
ated by extrinsic (e.g., growth factors or hor-
mones) and intrinsic (e.g., transcription factor
levels or somatic mutations) signals. The biolog-
ical outcome (whether the barriers are increased
or decreased) depends on which genes become aberrantly activated by the loss of chromatin repressive complexes (dashed lines). For instance, if a repressive
complex acts to limit the expression of an oncogene, loss of the complex would promote oncogenesis. Conversely, if the complex binds a tumor suppressor, its
loss would increase the barrier for oncogenic transformation. Thus, loss of a chromatin repressive complex can influence cell identity in different directions,
depending on the genes they regulate and the integration of the combined signals the affected cell receives.
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pression and defects during embryoid body formation with
incomplete silencing of pluripotency-associated genes (Foster
et al., 2010; Wang et al., 2009a). Lsd1 has also been shown
to colocalize with NuRD at the enhancers of pluripotency-
associated genes, where it is required for the downregulation
of H3K4me1-levels during differentiation (Whyte et al., 2012).
Chromatin Repressive Complexes and Pluripotency. Many
repressive complexes do not seem to be essential for the self-
renewal of ESCs, while both in vivo and in vitro data demonstrate
their requirement for pluripotency. It has been suggested that
one of the key functions of chromatin regulation is in noise reduc-
tion, meaning that the presence of nucleosomes and other
chromatin-bound factors act to limit the propensity of promiscu-
ous transcriptional activity such that several cues need to act
in concert in order for transcription to take place (Figure 3).
Studies from yeast support this theory: By competing with tran-
scription factors and the transcriptional machinery for access to
promoters, chromatin acts to increase the threshold for gene
activation and limit transcriptional noise (Lam et al., 2008; see
also, e.g., Chi and Bernstein, 2009). This view might help explain
the phenotype of ESCs lacking chromatin repressive com-
plexes: As long as cells are grown in defined media, loss of a
complex does not lead to widespread gene activation or
changes in cell identity. However, it might lower the threshold
for gene activation giving rise to transcriptional noise. Thus,
during differentiation in an environment with multiple signals
and different types of cells, the more relaxed chromatin
makes cells lacking repressive complexes more susceptible
to aberrant activation of gene expression, which can result in
differentiation and developmental failures. The normal role of
the repressive chromatin complexes is therefore to ensure that
sustained and strong signals are required for changing the
transcription program and the specification of differentiation.
The importance of defined media in this context is illustrated
by the early observations that knockout of e.g., Ezh2 or Mbd3
was incompatible with the establishment of pluripotency (Kaji
et al., 2007; O’Carroll et al., 2001). Both observations have
since been refuted by the establishment of knockout mESCs
lacking either factor, most likely through the refinement of
experimental procedures or the introduction of optimized
culture conditions such as 2i/LIF (Rais et al., 2013; Shen et al.,
2008).In the context of pluripotent cells, a much-debated feature is
the observation of bivalent domains in the promoters of develop-
mental genes, defined by the presence of H3K4me3 alongside
H3K27me3 (Azuara et al., 2006; Bernstein et al., 2006). This
co-occurrence observed by ChIP-sequencing approaches
might represent the two marks existing simultaneously on the
same histone tail, on opposite H3 tails of the same nucleosome
or on neighboring nucleosomes. In addition, it has been argued
that bivalent promoters might simply represent an artifact of het-
erogeneous cell populations. Although additional observations
of bivalent domains in the early embryo and differentiated cell
types and the application of sequential ChIP and mass spec-
trometry approaches have shown the existence of truly bivalent
promoters, their functional relevance remains unclear. With all
CpG-rich promoters being H3K4me3-positive inmESCs (Mikkel-
sen et al., 2007) and PRC2 being recruited to CpG-rich stretches,
the co-occurrence of H3K4me3 and H3K27me3 is to be ex-
pected. Bivalent genes are found to be transcriptionally inactive
but are generally thought to be poised for activation upon differ-
entiation, thus providing plasticity to the chromatin structure
(Voigt et al., 2013). However, recent studies show that loss of
H3K4me3 from bivalent promoters does not disrupt the large-
scale responsiveness of gene activation upon all trans-retinoic-
acid-induced differentiation of mESCs, thus questioning the
prevailing view of the functional relevance of bivalency (Denissov
et al., 2014; Hu et al., 2013).
ChIP analyses show binding of the Chd4 component of NuRD
at bivalent polycomb target gene promoters and reveal potential
coregulation of the two complexes with common target genes
gaining H3K27ac and losing PRC2 binding, as well as
H3K27me3 in Mbd3/ cells (Reynolds et al., 2012b). This indi-
cates that NuRD and PRC2 might be functionally linked through
occupation of some of the same genomic loci, where NuRD
might facilitate PRC2 recruitment and methylation through de-
acetylation of H3K27. This potential coregulation is reminiscent
of observations in Drosophila, where HDAC1/RPD3 collaborates
with PcGs in repressing a subset of PcG target genes (Tie et al.,
2001).
Interestingly, Hdac1 and Mbd3 have been found to associate
with the promoters of many actively transcribed genes, including
core pluripotency factors. Importantly, however, comparative
analysis of mESCs showed that target gene expression was pri-
marily upregulated upon Hdac1 knockout, indicating that NuRDCell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc. 739
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genes (Kidder and Palmer, 2012). In a recent study, Reynolds
et al. investigated the role of NuRD in regulating pluripotency
and lineagecommitmentofmESCs. Theauthors found that rather
than silencing pluripotency-associated genes, NuRD is required
to restrict transcript levels below a threshold, thereby sensitizing
cells to differentiation cues and facilitating lineage commitment in
response to the relevant stimuli (Reynolds et al., 2012a). Thus,
NuRD and other repressive complexes might not function as
traditional silencers but rather by fine-tuning expression levels
of their target genes (Hu andWade, 2012; Reynolds et al., 2013).
In the acquisition of pluripotency through reprogramming of
somatic cells, the chromatin environment undergoes major reor-
ganization toward an open chromatin structure along with
erasure of DNA methylation and redistribution of histone modifi-
cations, and many chromatin modifiers appear to influence this
process. Cell fusion experiments with mESCs with knockout of
PRC1 or PRC2 components show that functional PRCs are
required for reprogramming of human B cells (Pereira et al.,
2010). Similarly, small hairpin RNA-mediated knockdown of
PRC1 or PRC2 components impaired the conversion of human
fibroblasts to induced pluripotent stem cells (iPSCs) (Onder
et al., 2012), while ectopic Ezh2 or Bmi1 expression increases
the efficiency of iPSC generation (Buganim et al., 2012; Moon
et al., 2011). In this context, it is important to keep in mind the dif-
ferences between mouse and human pluripotent cells. Indeed,
Ezh2 knockout does not impair iPSC formation from MEFs (Fra-
gola et al., 2013), indicating that Ezh2 is not required for reprog-
ramming of mouse cells. However, the authors note that despite
a global loss of H3K27me3 upon Ezh2 knockout, this mark is re-
tained on a subset of important developmental regulators, most
likely deposited by Ezh1-PRC2. Indeed, knockdown of Eed in the
Ezh2-deficient cells diminishes the remaining H3K27me3 and
prohibits reprogramming (Fragola et al., 2013). Another impor-
tant aspect to consider is the potentially distinct requirements
of repressive complexes during early and late stages of reprog-
ramming (Ho et al., 2013), as well as effects on proliferation,
which are not directly linked to the acquisition of pluripotency,
yet would still influence reprogramming efficiency.
Whereas the PRCs are observed to positively influence re-
programming, the opposite situation has been reported for other
repressive chromatin regulators. Recently, depletion of the core
NuRD component Mbd3 was shown to increase the efficiency of
iPSC generation (Luo et al., 2013; Rais et al., 2013). One expla-
nation for the seemingly discrepant roles of these repressor
complexes might be that PRCs are primarily involved in repres-
sion of differentiation-associated genes, while NuRD also plays
important roles in the regulation of pluripotency-associated
genes. In contrast, however, a separate study shows that
Mbd3 is required for the establishment of iPSCs from mouse
neural stem cells, as well as the more primed epiblast stem cells
and preiPSCs, while ectopic expression of Mbd3 with Nanog
promotes reprogramming (dos Santos et al., 2014). These
discrepancies might stem from differences in the experimental
approaches and culture conditions applied, underlining the
context-dependent nature of such studies.
Collectively, a plethora of studies demonstrate important roles
of chromatin repressive complexes in governing cell identity and
guarding the pluripotent state of ESCs. Tables 1 and 2 summa-740 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.rize the observed phenotypes of loss-of-function studies con-
cerning repressive complexes components in pluripotent cells.
Chromatin Repressive Complexes in Tissue Stem Cells
and Development
During embryonic development, the chromatin environment is
modulated to facilitate specification and maintenance of the
various cell types. Accordingly, many components of chromatin
repressive complexes are required for normal development. The
exact phenotypes vary according to the specific component
investigated, but general features include defects in early lineage
specification upon knockout of Ring1b or core PRC2 members
(Faust et al., 1995; O’Carroll et al., 2001; Pasini et al., 2004;
Voncken et al., 2003) and several members of HDAC1 and
HDAC2-containing complexes (Cowley et al., 2005; David
et al., 2003; Hendrich et al., 2001; Lagger et al., 2002; Wang
et al., 2007a), as well as later developmental problems with de-
fects in cell type specification and tissue development as
observed for several components. In the context of PRC2, it is
noteworthy that Jarid2 knockout leads to defects in neural
tube formation with embryonic lethality around E15.5 (Takeuchi
et al., 1995), whereas Pcl2 knockout mice display an incom-
pletely penetrant phenotype of skeletal transformation (Wang
et al., 2007b), providing evidence that neither interacting protein
is solely responsible for PRC2 recruitment.
Interestingly, the existence of multiple homologs of certain
components appears to provide some functional redundancy
during development. For instance, mice lacking the PRC1
component Pcgf2/Mel18 or the closely related gene Pcgf4/
Bmi1 are viable with homeotic transformations (Akasaka et al.,
1996; van der Lugt et al., 1994), while concomitant deletion of
both genes leads to embryonic lethality around E9.5 (Akasaka
et al., 2001). In the context of multiple homologs, important fac-
tors to consider include spatiotemporal expression patterns, as
well as potential distinctive functions of the homologous pro-
teins, which can give rise to distinct phenotypes of loss of single
homologs. This is exemplified by the fact that knockout of Ezh2,
Ring1b, Hdac1, or Sin3a leads to early embryonic lethality,
whereas the loss of their closely related structural homologs
have less severe consequences on development. The observed
phenotypes from knockout studies of components of Polycomb
group proteins and HDAC1 and HDAC2-containing complexes
are summarized in Tables 1 and 2.
In addition to their roles during early embryonic development,
chromatin repressive complexes play important roles in main-
taining gene-expression patterns and cell identity of many
different tissues. The roles of PRCs and HDAC1- and HDAC2-
containing complexes in tissue stem cells and development
are discussed below and summarized in Tables S1 and S2 avail-
able online.
Polycomb Repressive Complexes in Tissue Stem Cells and
Development. The PRCs have been most extensively studied
in mESCs, but a growing number of studies demonstrate impor-
tant roles of PRCs in tissue-specific stem and progenitor cells,
and conditional knockout studies show that the PRCs are
required during many aspects of mammalian development.
In the hematopoietic system, Bmi1 is required for self-renewal
of hematopoietic stem cells (HSCs) through a mechanism
involving the repression of the Ink4a-Arf locus (Park et al.,
2003), and Bmi1 knockout promotes premature and deficient
Table 1. Loss-of-Function Phenotypes of Polycomb Repressive Complexes
Development mESCs Reprogramming References
PRC1
Ring1a Viable with homeotic transformation. Knockdown impairs reprogramming. (del Mar Lorente et al., 2000;
Onder et al., 2012)
Ring1b Lethal around E10.5. Gastrulation
defects and cell-cycle inhibition.
Global loss of H2AK119ub1. Slight
deregulation of target genes. Differentiation
defects.
(de Napoles et al., 2004; Leeb and
Wutz, 2007; Voncken et al., 2003)
Ring1a/Ring1b
double KO
Loss H2AK119ub1 (also on Xi), derepression
of target genes, loss of self-renewal and
differentiation defects.
Knockout impairs reprogramming. (de Napoles et al., 2004; Endoh
et al., 2008; Pereira et al., 2010)
Pcgf2 (Mel18) Homeotic transformation, postnatal
lethality.
(Akasaka et al., 1996)
Pcgf4 (Bmi1) Homeotic transformation, neurological
and immune defects with peri- or
postnatal lethality.
Knockdown impairs and overexpression
enhances efficiency.
(Moon et al., 2011; Onder et al.,
2012; van der Lugt et al., 1994)
Pcgf2/Pcgf4
double KO
Lethal around E9.5. (Akasaka et al., 2001)
Cbx2 (M33) Homeotic transformation and severe
immune defects. 50% die perinatally.
Remaining pups die postnatally.
(Core´ et al., 1997)
Cbx4 Perinatal lethality with severe immune
defects.
(Liu et al., 2013)
Cbx7 Increased susceptibility to tumors of
liver and lung.
(Forzati et al., 2012)
Knockdown yields differentiation defects. (Morey et al., 2012)
Phc1 (Rae28) Perinatal lethality and homeotic
transformation.
(Takihara et al., 1997)
Phc2 Viable with homeotic transformation. (Isono et al., 2005)
Phc1/2 double KO Lethal before E11.5. (Isono et al., 2005)
Rybp Early postimplantation lethality around
E6.5.
Knockdown yields reduction of H2AK119ub1
and differentiation defects.
(Gao et al., 2012; Pirity et al., 2005)
L3mbtl2 Lethal around E9.5. Gastrulation
defects.
Decreased proliferation. Differentiation defects. (Qin et al., 2012)
Kdm2b (Fbxl10) Incompletely penetrant peri-/postnatal
lethality with defects in neural tube
closure.
Knockdown yields reduction of H2AK119ub1
and differentiation defects.
Knockdown impairs and overexpression
enhances efficiency.
(Fukuda et al., 2011; Liang et al.,
2012; Wu et al., 2013)
(Continued on next page)
C
e
ll
S
te
m
C
e
ll
1
4
,
J
u
n
e
5
,
2
0
1
4
ª
2
0
1
4
E
ls
e
v
ie
r
In
c
.
7
4
1
C
e
ll
S
te
m
C
e
ll
R
e
v
ie
w
Table 1. Continued
Development mESCs Reprogramming References
PRC2
Ezh2 Lethal around E7.5-8.5. Gastrulation
defects.
Global loss of H3K27me2/3, differentiation
defects.
Knockout/knockdown impairs
reprogramming of human cells.
Overexpression enhances, yet
knockout does not impair mouse
iPSC formation.
(Buganim et al., 2012; Fragola et al.,
2013; O’Carroll et al., 2001; Onder
et al., 2012; Pereira et al., 2010;
Shen et al., 2008)
Ezh1 Not required. (Onder et al., 2012)
Eed Lethal around E7.5-8.5. Gastrulation
defects.
Global loss of H3K27me2/3, slight
derepression of target genes and differentiation
defects. Late-passage Eed/ cells: Global loss
of H3K27me1 and further derepression.
Knockout impairs reprogramming. (Chamberlain et al., 2008; Faust
et al., 1998; Faust et al., 1995;
Montgomery et al., 2005; Pereira
et al., 2010; Schumacher et al.,
1996)
Suz12 Lethal around E7.5-8.5. Gastrulation
defects.
Global loss of H3K27me2/3, differentiation
defects.
Knockout impairs reprogramming. (Pasini et al., 2007; Pasini et al.,
2004; Pereira et al., 2010)
Jarid2 Lethal at E11.5-15.5 with developmental
defects depending on strain.
Differentiation defects. Not required. (Lee et al., 2000; Motoyama
et al., 1997; Pereira et al., 2010;
Shen et al., 2009; Takeuchi
et al., 1999; Takeuchi et al., 1995)
Pcl2 Viable with incompletely penetrant
defects including homeotic
transformations.
Knockdown yields enhanced self-renewal and
differentiation defects.
(Walker et al., 2010; Wang et al.,
2007b)
Pcl3 Knockdown yields differentiation defects. (Brien et al., 2012)
Yy1 Peri-implantation lethality. Knockdown enhances efficiency. (Donohoe et al., 1999; Onder et al.,
2012)
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Table 2. Loss-of-Function Phenotypes of Hdac1- and Hdac2-Containing Complexes
Development mESCs Reprogramming References
Hdac1 and Hdac2
Hdac1 Lethal E9.5-10.5. Decreased proliferation
and differentiation defects.
(Dovey et al., 2010;
Lagger et al., 2002)
Hdac2 Perinatal lethality with
cardiac malformations.
Not effect on self-renewal
or pluripotency.
(Dovey et al., 2010;
Montgomery et al., 2007)
Hdac1 and
Hdac2
Valproic acid
increases efficiency.
(Huangfu et al., 2008)
Sin3
Sin3a Peri-implantation lethality. Insufficient outgrowth
of ICM during mESC
establishment.
(Cowley et al., 2005;
Dannenberg et al., 2005)
Sin3b Perinatal lethality. Pups born
in submendelian ratios.
(David et al., 2008)
Sds3 Peri-implantation lethality. Defects
in chromosome segregation and
early lineage specification.
(David et al., 2003)
NuRD
Mbd2 Mice are viable. Abnormal
maternal behavior.
(Hendrich et al., 2001)
Mbd3 Early postimplantation lethality. Differentiation defects. Conflicting data:
Knockout/knockdown
enhances efficiency.
Knockout impairs
and ectopic expression
enhances efficiency.
(Hendrich et al., 2001;
Kaji et al., 2006; Luo et al.,
2013; Rais et al., 2013)
(dos Santos et al., 2014)
Gatad2a Postimplantation lethality,
morphological defects.
(Marino and Nusse, 2007)
CoREST
CoREST Late embryonic lethality
due to severe anemia.
(Yao et al., 2014)
Lsd1 Early embryonic lethality
around E5.5 with defects
in gastrulation and
trophoblast specification.
Reduced CoREST levels,
slight deregulation of
gene expression and
differentiation defects.
(Foster et al., 2010;
Wang et al., 2009a;
Wang et al., 2007a;
Zhu et al., 2014)
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specific composition of PRC1 with regards to the Cbx compo-
nent seems to be important for the transition from self-renewal
to differentiation during hematopoiesis. As in mESCs, Cbx7 is
required for HSC self-renewal, whereas Cbx2/4/8-containing
PRC1 seems to be important during differentiation (Klauke
et al., 2013). In addition, overexpression of Cbx7 or Kdm2b pro-
motes HSC self-renewal and the number of colony-forming
cells during serial transplantations (Klauke et al., 2013; Konuma
et al., 2011). Studies of PRC2 in the hematopoietic system
show that Ezh2 is required for normal lymphopoiesis (Su et al.,
2003) and PRC2 is involved in HSC self-renewal with Ezh2
being important for HSC self-renewal during fetal liver
hematopoiesis, while Ezh1 maintains the HSC compartment in
the adult bone marrow (Hidalgo et al., 2012; Mochizuki-Kashio
et al., 2011), once again highlighting the importance of
context-specific incorporation of different homologs. Given the
many recent reports of increased expression levels and loss-
of-function mutations of PRC2 members, as well as hyperactive
oncogenic EZH2 mutants in hematopoietic cancers, it is highlyrelevant to further study the role of PRCs in normal andmalignant
hematopoiesis.
PRCs also contribute the self-renewal capacity of neural stem
cells by maintaining the Ink4a-Arf locus in a repressed state
(Molofsky et al., 2003), and they are involved in the timely repres-
sion of neurogenic factors, promoting the neurogenic-to-astro-
genic switch (Hirabayashi et al., 2009; Roma´n-Trufero et al.,
2009). Important roles of the PRCs have also been described
in epidermal stem cells, skeletal and cardiac muscle, hepatic
stem cells, and in the skeletal system (Table S1).
While many studies have shown the requirement of PRCs for
maintaining the differentiation capacity of both mESCs and tis-
sue-specific stem cells, PRC components appear to be specif-
ically required for self-renewal of a wide range of tissue-specific
stem cells. The basis for this differential requirement is not
entirely clear, but the consideration of several factors could pro-
vide some explanation: The use of defined media and culture
conditions might influence the outcome of loss-of-function
studies, as illustrated by the fact that some of the phenotypes
observed in mESCs grown in serum/LIF have been refuted byCell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc. 743
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nous cell populations influenced by fewer environmental cues.
Furthermore, lineage-committed tissue-specific stem cells
residing in more complex and heterogeneous environments or
grown in less well-defined media outside their niche might be
more sensitive to the loss of chromatin factors. During differen-
tiation, the chromatin environment changes to a more restrictive
conformation with accumulation of repressive chromatin marks
such as H3K27me3 (Zhu et al., 2013). In the context of lineage-
committed cells, loss of PRC2 would influence this organization,
leading to failures in differentiation and/or altering develop-
mental potential, as illustrated by the enhanced plasticity
observed in Ezh2-deficient T cells (Tumes et al., 2013).
Hdac1- and Hdac2-Containing Complexes in Tissue Stem Cells
and Development. While Hdac1 and Hdac2 are considered to
act redundantly in most cell types, important exceptions to this
view include distinct roles during early embryogenesis, where
Hdac1 is essential and required for proliferation through repres-
sion of cell-cycle inhibitors (Lagger et al., 2002). In addition, con-
ditional knockout studies with combinatorial ablation of Hdac1
andHdac2 demonstrate distinct roles during epidermal develop-
ment, where loss of a single allele of Hdac2 in an Hdac1
knockout background leads to developmental defects (Winter
et al., 2013), and the opposite situation in neuronal development,
where Hdac1 haplo-insuffiency is observed in Hdac2 knockouts
(Hagelkruys et al., 2014).
Studies in knockout mice and tissue-specific stem cells show
important roles of Hdac1 and Hdac2-containing complexes in
many different tissues, including roles of NuRD, Sin3, and
CoREST in the hematopoietic system (Cowley et al., 2005; David
et al., 2008; Kerenyi et al., 2013; Williams et al., 2004; Yao et al.,
2014; Yoshida et al., 2008; Zhang et al., 2012b), roles of NuRD in
epidermal stem cells (Kashiwagi et al., 2007), and roles of REST/
CoREST and Lsd1 in neural stem cells and during neural devel-
opment (Qureshi et al., 2010; Sun et al., 2010;Wang et al., 2007a)
(Table S2).
Taken together, chromatin repressive complexes are essential
for establishing and maintaining cell identity during tissue devel-
opment and homeostasis, in part through their ability to restrict
the expression of important cell-cycle regulators and key devel-
opmental genes. One emerging picture is that subunit composi-
tion and association with specific interactors provide important
means for regulating the function of the complexes in different
cell types and developmental stages. Further elucidation of the
molecular basis of tissue-specific functions of repressor com-
plexes will be crucial for understanding the consequence of their
deregulation in cancer.
Chromatin Repressive Complexes in Cancer
Many cancers display a dedifferentiated stem cell-like pheno-
type, and several of the factors required for establishing or main-
taining stem cell states are also involved in oncogenesis. Thus,
bearing in mind that chromatin repressors are crucial for estab-
lishing and preserving cellular identity, it is to be expected that
chromatin repressors would often be found deregulated in
human cancers. Intense research is going into elucidating the
mechanism by which chromatin modifiers and modifications
promote cancer development or progression. One of the early
recurring questions in cancer epigenetics was that of ‘‘cause
or consequence,’’ that is, whether the chromatin environment744 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.is deregulated as a consequence of the cancer or if the chro-
matin regulators play a direct role in driving oncogenesis. How-
ever, recent discoveries of copious numbers of recurrent
somatic mutations in genes encoding chromatin-associated
proteins argue that a deregulated chromatin environment can
play a causal role in the disease (You and Jones, 2012). In the
following, we will discuss reports of deregulated chromatin
repressors and their emerging roles as targets for anticancer
therapeutics.
Polycomb Repressive Complexes and Cancer. Increased
levels of EZH2 have been correlated with poor outcome in met-
astatic prostate cancer and poor prognosis in tumors of other
tissues (Bracken et al., 2003; Kleer et al., 2003; Takawa et al.,
2011; Varambally et al., 2002; Wagener et al., 2010). Recently,
recurrent point mutations in the SET domain of EZH2 have
been described in diffuse large B cell lymphoma and follicular
lymphoma, conferring hyperactivity of EZH2 yielding increased
levels of H3K27me3 (Be´guelin et al., 2013; Lohr et al., 2012;
McCabe et al., 2012a; Morin et al., 2010; Pasqualucci et al.,
2011; Ryan et al., 2011). Further evidence for direct roles of
H3K27 methylation in cancer includes loss-of-function muta-
tions of the demethylase UTX (Dalgliesh et al., 2010; van Haaften
et al., 2009) and the recent discoveries of somatic mutations of
lysine 27 in H3.3 in pediatric glioblastoma (Schwartzentruber
et al., 2012; Wu et al., 2012). However, this mutation has been
shown to inhibit PRC2 activity, leading to lower H3K27me3
levels. Loss-of-function mutations of EZH2, as well as SUZ12,
EED, and JARID2, have been identified in myeloid cancers (Ernst
et al., 2010; Nikoloski et al., 2010; Puda et al., 2012; Ueda et al.,
2012) and T-ALL (Ntziachristos et al., 2012; Simon et al., 2012;
Zhang et al., 2012a), as well as cancers of other tissues. Thus,
the role of PRC2 in cancer is highly context dependent with
EZH2 exerting functions as an oncogene as well as a tumor
suppressor.
Indications of PRC1 involvement in human cancer include
increased expression levels of BMI1 and correlation with poor
prognosis in a range of solid tumors and hematological cancers
(Heet al., 2009;Mohty et al., 2007;Nowaket al., 2006; Shafaroudi
et al., 2008) and reports of oncogenic functions of CBX7 in the
hematopoietic system (Klauke et al., 2013; Scott et al., 2007)
and some solid tumors (Shinjo et al., 2013; Zhang et al., 2010),
as well as tumor suppressor roles in others (Forzati et al., 2012).
HDAC1- and HDAC2-Containing Complexes and Cancer.
While somatic mutations in HDACs are rare, there are many re-
ports of HDAC1 and HDAC2 being overexpressed in human can-
cers, often correlating with poor patient outcome. In contrast,
there is also data on cancer-associated loss-of-function muta-
tions of HDAC1 and HDAC2, and knockout mouse models
show that these proteins can also exert tumor suppressive roles
(West and Johnstone, 2014). In addition, HDACs are aberrantly
recruited to target genes in many cancers, in part due to an
altered expression level of specific subunits of the HDAC-con-
taining complexes. The SIN3-associated protein BRMS1 is often
lost in invasive stages of human cancers (Hurst, 2012), and ING1
and ING2 are often mutated or downregulated in human can-
cers, pointing to tumor suppressive roles of SIN3 (Gue´rillon
et al., 2014). The MTA subunits are the most studied compo-
nents of NuRD with a role in cancer. As the name implies,
MTA1 (metastasis associated gene 1) was originally identified
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increased expression in a wide range of tumors correlates with
tumor grade and poor prognosis (Nicolson et al., 2003). Interest-
ingly, there is an inverse correlation between MTA1 and MTA3
expression during cancer progression, and MTA3 seems to
play mainly tumor suppressive functions, thus pointing to the
importance of specific subunit composition in regulating com-
plex function (Lai and Wade, 2011). ZNF217 is overexpressed
in cancers and was found to recruit CoREST to the INK4B locus
(Thillainadesan et al., 2012), thus promoting proliferation, and
LSD1 expression is elevated in many human cancers (Helin
and Dhanak, 2013) but is also reported to be downregulated
and involved in the suppression of metastasis in breast cancers
(Wang et al., 2009b). Whether LSD1 exerts its functions in cancer
mainly as a subunit of NuRD, CoREST, or along with additional
factors remains to be elucidated.
Molecular Mechanisms of Chromatin Repressive Complexes in
Cancer. The mechanisms by which repressive-complex pro-
teins contribute to oncogenesis include their roles in repressing
genes activated by stress signals and involved in proliferation.
PcG proteins bind the INK4A-ARF-INK4B locus, and overex-
pression of PcG proteins prevents expression of p14 (ARF),
p15 (INK4B), and p16 (INK4A) in response to stress signals,
including oncogenes (Bracken et al., 2007). Although cancer
cells generally display global DNA hypomethylation, CpG islands
of tumor-suppressor genes are often aberrantly methylated in
cancer. Interestingly, PcG binding has been suggested to pre-
dispose promoters for DNA hypermethylation (Ohm et al.,
2007; Schlesinger et al., 2007; Widschwendter et al., 2007).
Oncogenic fusion proteins have been implicated in aberrant tar-
geting of repressive complexes to chromatin, including PLZF-
RARa-mediated recruitment of PRC1 and PML-RARa-mediated
recruitment of PRC2, DNMTs, and NuRD in leukemia (Lai and
Wade, 2011; Richly et al., 2011). NuRD, LSD1, and PcG proteins
have been shown to promote the epithelial-to-mesenchymal
transition (EMT) through TWIST- or SNAIL1-mediated downre-
gulation of E-cadherin (Tam and Weinberg, 2013), and EZH2
overexpression seems to promote tumor angiogenesis (Lu
et al., 2010). Another important aspect is the role of repressive
complexes in governing cell identity: indeed, aberrant expres-
sion of PcG proteins helps sustain a dedifferentiated phenotype
as seen for instance in rhabdomyosarcoma, where knockdown
studies and application of specific inhibitors targeting EZH2
are able to partially reinstate muscle cell identity to the tumor
cells (Marchesi et al., 2012).
Although the involvement of chromatin repressive complexes
in cancer is indisputable, their functional role in oncogenesis is
still incompletely understood as they promote oncogenesis in
one setting, while protecting against malignant transformation
in another. This duality is probably related to the role of chro-
matin modifiers in modulating transcriptional output of target
genes with opposing functions. Rather than directly deciding
the transcription programs, alterations in the level of chromatin
regulators changes the threshold for transcriptional activation
or repression and this altered chromatin balance sensitizes the
cell to stimuli promoting oncogenic transformation. Deciphering
the role of repressive complexes in specific cancer types will be
important for furthering our understanding and guiding new
therapies.Targeting Chromatin Repressive Complexes in Cancer
While genetic lesions are difficult to target therapeutically, tar-
geting the deregulated chromatin environment is tempting due
to the reversibility of the system. Several drugs targeting chro-
matin modifiers are already being used in the clinic. Most
famously, DNA methyltransferase inhibitors are used to treat
patients with MDS, where they prolong lifespan and prevent
the progression to leukemia (Helin and Dhanak, 2013).
HDAC Inhibitors. Another class of molecules already being
used in the clinic is HDAC inhibitors, which are currently used
in the treatment of T cell lymphoma. The FDA-approved Vorino-
stat and Romidepsin target class I HDACs and are able to inhibit
the function of HDAC1 and HDAC2 in the context of SIN3, NuRD,
and CoREST (Khan and La Thangue, 2012;West and Johnstone,
2014). The molecular mechanisms of these drugs are still incom-
pletely understood, but treatment outcomes include cell-cycle
arrest via induction of p21, increased apoptosis, antiangiogenic
effects via HIF1 inhibition, and sensitization of cancer cells to
DNA-damaging agents (Khan and La Thangue, 2012). Despite
these encouraging results, there is no clear correlation between
acetylation levels and clinical outcome upon HDAC inhibition. In
addition, it has been difficult to establish robust biomarkers to
predict efficacy, and, thus far, these drugs are limited to treat-
ment of specific hematological cancers (Helin and Dhanak,
2013).
LSD1 Inhibitors. In addition to HDAC inhibitors, LSD1 inhibition
represents a route of targeting complexes such as NuRD and
CoREST. Two recent studies have provided evidence for an
important role of LSD1 in acute myeloid leukemia (Harris et al.,
2012; Schenk et al., 2012). Neither study observes any global
effect on histonemethylation, but both report localized increases
in H3K4me2 at specific promoters, including the differentiation
marker CD11b (Schenk et al., 2012), and certain MLL-AF9 tar-
gets (Harris et al., 2012). These studies raise several questions
regarding the function of LSD1 in leukemia: First, LSD1 binds
throughout the genome as part of several different complexes,
yet the effects on H3K4me2 are very localized. Second, although
LSD1 inhibition leads to an increase in CD11b expression
(Schenk et al., 2012), the increased H3K4me2 at MLL-AF9 target
genes is actually accompanied by lower expression (Harris et al.,
2012), which is surprising considering that H3K4me2 is usually
associated with gene expression. Thus, although these studies
are encouraging, the mechanisms underlying the differentiation
and apoptosis-inducing properties of LSD1 inhibitors remain to
be elucidated.
EZH2 Inhibitors. With EZH2 being overexpressed in many can-
cers and the recent reports on hyperactive EZH2 mutants in
follicular lymphoma and diffuse large B cell lymphoma, specific
EZH2 inhibitors are attracting interest as potential anticancer
drugs. Several highly selective compounds show promising re-
sults in reducing H3K27me3 levels, decreasing proliferation,
and increasing apoptosis in lymphoma cell lines carrying SET
domain mutations and markedly reducing tumor burden and
increasing survival in mouse xenograft models (Knutson et al.,
2014; Knutson et al., 2012; McCabe et al., 2012b; Qi et al.,
2012), and two EZH2 inhibitors have entered clinical trials
(www.clinicaltrials.gov). Interestingly, EZH2 inhibition has also
been shown to inhibit the growth of rhabdoid tumors and
lowering intratumor levels of H3K27me3, potentially expandingCell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc. 745
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(Knutson et al., 2013). These pediatric tumors arise from a loss
of the SNF5 component of the SWI/SNF remodeling complex
(Versteege et al., 1998). They display elevated EZH2 levels,
and conditional knockout of Ezh2 has been shown to reduce tu-
mor growth (Wilson et al., 2010). Interestingly, this type of tumor
only carries few somatic mutations (Lee et al., 2012), potentially
making them more dependent on the chromatin environment
and onemight speculate that other tumor types with few somatic
mutations could show similar vulnerability to PRC2 inhibitors.
Importantly, despite clear effects on prohibiting cancer growth,
it has not been possible to identify consistent transcriptional
profiles being reverted upon treatment with EZH2 inhibitors
(McCabe et al., 2012b). This lack of consistency indicates that
EZH2 targets different pathways even within the same types of
tumors, in agreement with a role of chromatin factors in threshold
modulation as opposed to directly deciding the transcriptional
outcome. With EZH2 exhibiting characteristics of an oncogene
as well as a tumor suppressor even within hematological can-
cers, it will be important to develop tools and biomarkers to
predict efficacy of targeting EZH2 therapeutically and to stratify
patients accordingly.
Alternative Ways of Targeting Polycomb Repressive Complexes.
In the context of targeting PcG proteins in cancer, several new
drugs are currently being tested. One approach, targeting the
EED-EZH2 interface by treatment with a stabilized a-helix of
EZH2, showsdisruption of PRC2complex formation, lower levels
of H3K27me3, growth arrest, and differentiation of MLL-AF9
driven leukemic cells (Kim et al., 2013). In the context of targeting
PRC1, application of small-molecule BMI1 inhibitors reduced
global H2AK119ub1 in colorectal cancer cells and decreased
tumor load in transplanted mice through a depletion of cancer-
initiation cells (Kreso et al., 2014). Another potential approach
to targeting PRC1 is by chromodomain inhibitors targeting the
CBX-component. Recently, Simhadri et al. reported on thedevel-
opment of a chromodomain antagonist with 10- to 400-fold
selectivity for CBX7 over other CBX family members (Simhadri
et al., 2014). In addition, studies of BET (bromodomain and extra-
cellular) domain inhibitors targeting BRD4 indicate that targeting
domains recognizing histone modifications is therapeutically
feasible (Di Croce and Helin, 2013). With its oncogenic roles in
thehematopoietic systemandCBX7beingpreferentially involved
in undifferentiated cell types, it will be interesting to explore
CBX7 inhibition as a strategy for targeting PRC1 in cancer.
Concluding Remarks
The chromatin environment is an important factor in the estab-
lishment and maintenance of cell identity. Accordingly, the pro-
tein complexes modulating chromatin are important for many
aspects of mammalian development and stem cell function
and are often deregulated in cancers. Although the introduction
of DNA demethylating agents and HDAC inhibitors in the clinic
provides proof-of-concept of the feasibility of targeting the chro-
matin environment in cancer, and the ongoing development of
drugs targeting chromatin modifiers show promising results in
preclinical trials, the mechanisms underlying their efficacy are
not understood. Thus, further elucidation of the role of chromatin
repressive complexes in cancer and the development of robust
predictive biomarkers will be paramount in the implementation
of personalized therapies to improve patient outcome.746 Cell Stem Cell 14, June 5, 2014 ª2014 Elsevier Inc.SUPPLEMENTAL INFORMATION
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